AA
NTLA icon

AlphaMark Advisors’s Intellia Therapeutics NTLA Stock Holding History

AlphaMark Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$17K Buy
+1,500
New +$23.4K 0.01% 375
2019
Q2 		– Sell
-172
Closed -$3K – 523
2019
Q1 		$3K Hold
172
– – ﹤0.01% 444
2018
Q4 		$2K Hold
172
– – ﹤0.01% 442
2018
Q3 		$5K Buy
+172
New +$5K ﹤0.01% 426

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaMark Advisors's NTLA Position: Q4 2024 in Review

AlphaMark Advisors opened a new position in Intellia Therapeutics (NTLA) in Q4 2024: 1,500 shares worth $17K. The stake represents 0.01% of the portfolio and ranks #375 among its holdings. This is a return to the name: AlphaMark Advisors previously reported a position in NTLA as recently as Q1 2019.

AlphaMark Advisors first reported a position in NTLA in Q3 2018 and has held it in 4 quarters since. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • AlphaMark Advisors held 1,500 shares of Intellia Therapeutics worth $17K as of Q4 2024.
  • Intellia Therapeutics was a new AlphaMark Advisors position in Q4 2024.
  • Intellia Therapeutics made up 0.01% of AlphaMark Advisors's portfolio in Q4 2024, its #375 holding.
  • AlphaMark Advisors first reported a position in Intellia Therapeutics in Q3 2018 and has held it in 4 quarters since.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.